Oncology News | pharmaphorum

News

Roche's oral SERD giredestrant fails breast cancer trial

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the eme

News

There are three types of white blood cells. T lymphocytes, B lymphocytes and natural killer cells.

Implants could transform CAR-T therapy into one-day procedur...

CAR-T therapies have revolutionised the treatment of some blood cancers, but are costly as well as time- and resource-intensive.

News

Regeneron seeks CheckMate in immuno-oncology play

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for M&A in

News

FDA starts speedy review of Enhertu in lung cancer

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its

News

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.<

News

Genmab and AbbVie prep filings for lymphoma bispecific

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead dr

Roche's oral SERD giredestrant fails breast cancer trial

Implants could transform CAR-T therapy into one-day procedur...

Regeneron seeks CheckMate in immuno-oncology play

FDA starts speedy review of Enhertu in lung cancer

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Genmab and AbbVie prep filings for lymphoma bispecific

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks